Retrospective Comparisons of Nanoparticle Albumin-Bound Paclitaxel and Docetaxel Neoadjuvant Regimens for Breast Cancer
Yan Li, Xiang Chen, Qiannan Zhu, Rui Chen, Lu Xu, Shuo Li, Xiaoqing Shi, Haiping Xu, Yinggang Xu, Weiwei Zhang, Xiaofeng Huang, Xiaoming Zha, Jue Wang
Abstract
Aim: To compare the efficacy and safety of 2-weekly nanoparticle albumin-bound paclitaxel (nP) and 3-weekly docetaxel regimens as neoadjuvant systemic therapy (NST) for breast cancer. Materials & methods: Patients (n = 201) received NST comprising either dose-dense epirubicin and cyclophosphamide followed by 2-weekly nP (n = 104) or 3-weekly courses of epirubicin and cyclophosphamide followed by docetaxel (n = 97). Results: Higher pathological complete response rates were achieved by the nP group. Subgroup analysis showed that the nP-based regimen achieved higher pathological complete response rates in patients with triple-negative tumor cells and high Ki67 levels. However, grades 3–4 peripheral sensory neuropathies were more frequent in the nP group. Conclusion: The 2-weekly nP-based regimen might be a better choice of NST for patients with breast cancer.